ClinicalTrials.gg
CompletedNCT04807218VICTORUpdated Mar 11, 2025

Virta Intervention in CommuniTies in cOloRado (VICTOR-Pilot)

An interventional study of Virta Health in Diabetes Mellitus, Type 2, sponsored by Colorado Prevention Center. Completed at 3 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Colorado Prevention Center · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,855th of 2,961
51 · median 90
Started
2021
with 171 others
No phase
1,242 of 3,308
200 open now
Registered
2,457th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,855th largest by enrollment of the 2,961 interventional ones that give a count, is one of 172 that started in 2021, is one of 1,242 with no phase, and was the 2,457th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The VICTOR study plans to include rural communities served by Colorado Heart Healthy Solutions (CHHS) program and find out whether participants will accept a referral to a comprehensive virtual lifestyle intervention, Virta Health. The Virta Health program induces nutritional ketosis to improve glucose control in individuals with type 2 diabetes. The study will inform the acceptability of the referral, the retention of participants in lifestyle intervention, and the durability of effects on glucose control after the lifestyle intervention has ended.

Read the detailed description

In rural communities served by Colorado Heart Healthy Solutions (CHHS), referral to a comprehensive remotely-delivered (virtual) continuous remote care to induce nutritional ketosis combined with remote medication management will improve glycemic control in patients with type 2 diabetes as compared with standard care. The study intervention is the referral. Subjects are not mandated to receive Virta treatment and are welcome to continue in the study whether or not the referral is accepted. 2 rural communities served by CHHS have been chosen as recruitment sites. Study patients will be randomized at the site level.

Objectives

Primary: To assess glycemic control in patients with type 2 diabetes living in a rural community referred to a comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management (termed "continuous remote care") as compared with those living in a rural community offered standard care.

Secondary:

  1. To assess the effects of referral to continuous remote care as compared with standard care on body weight and on body mass index
  2. To assess the effects of referral to continuous remote care as compared with standard care on number and doses of anti-hyperglycemic medications
  3. To determine the durability of a continuous remote care intervention when paired with ongoing community health worker support

    Exploratory:

  4. To assess the effects of referral to continuous remote care as compared with standard care on LDL-cholesterol, fasting glucose, and fasting triglyceride/HDL-cholesterol ratio
  5. To assess patient-reported outcomes of continuous remote care as compared with standard care
  6. To determine enrollment rate (offered vs accepted) in patients with type 2 diabetes living in rural communities referred to continuous remote care.
  7. To determine active engagement (number, timing, and types of 2-way contacts) and retention in patients with type 2 diabetes living in rural communities referred to continuous remote care.
03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Community Health Workers
  • Nutritional Ketosis
  • Patient Navigator
  • Diabetes
  • Referral
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide electronic
  2. Age 18 - 79 years old
  3. Type 2 diabetes mellitus diagnosis by self-report and/or medical history
  4. Taking 1 or more antihyperglycemic medications
  5. Current > 7.5%
  6. (BMI) 25 kg/m2 or greater
  7. Capable of engaging in virtual care

Exclusion criteria

Exclusion Criteria:

  1. Type 1 diabetes
  2. Pregnant or planning pregnancy within the next 9 months
  3. Lactating
  4. Admission for diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) within the last 12 months
  5. \<1 year
  6. Postural orthostatic tachycardia syndrome (POTS) and/or recurrent syncope
  7. Active severe psychiatric or medical condition(s) such as advanced renal (end-stage renal disease or CKD stage 4 or 5; \<30 mL/min), cardiac ( Class 4 heart failure), or hepatic dysfunction ( Class C)
  8. Any condition which in the opinion of the investigator would make the study unsuitable for the subject including investigator opinion regarding inability to comply with Virta instructions
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Active comparator
    Nutritional Ketosis Intervention Referral

    The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.

    Behavioral: Virta Health

  • Active comparator
    CHHS Standard Care - Delayed Referral to Nutritional Ketosis Intervention

    All subjects will be enrolled in Colorado Heart Healthy Solutions (CHHS), which consists of community health worker (CHW) contact and sessions on: 1) cardiovascular disease knowledge; 2) Health behavior change through skill building to improve diet (e.g., portion sizes, increasing fruit/vegetable intake, reducing intake of sugar sweetened beverages, decreasing fast food meals, etc.), increase physical activity, and improve well-being, tailored to individual subjects' risk profile and self-identified goals; and 3) Connection to services including primary care, mental health services if needed, and relevant community programs to address barriers (e.g. food insecurity, need for legal help) or to promote behavior change (e.g. free/low cost exercise programs).

    Behavioral: Virta Health

Interventions

  • BehavioralVirta Health

    The comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management is the Virta treatment, and while on this treatment, subjects will have access to Virta health coaches and licensed medical providers who will perform medical therapy management, health coaching, nutrition and behavior change education, biometric feedback, and the option to participate in a community for peer support.

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin A1c (Percent)

    Change from baseline hemoglobin A1c (Percent) among patients referred to continuous remote care (Group 1) versus standard care (Group 2)

    Time frame: 3.5 months

Secondary outcomes

  1. Change in BMI

    Among Group 1 versus Group 2 subjects, change in body mass index (kg/m2)

    Time frame: Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus10 months

  2. Change in hemoglobin A1c

    Among Group 1 versus Group 2 subjects, difference in hemoglobin A1c

    Time frame: 3.5 months versus 7 months, baseline versus 10 months

  3. Change in number and/or doses of anti-hyperglycemic medications • doses of anti-hyperglycemic medications

    Among Group 1 versus Group 2 subjects, difference in: * number of anti-hyperglycemic medications * doses of anti-hyperglycemic medications

    Time frame: Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus 10 months

Other outcomes

  1. Acceptance of referral to continuous remote care

    Proportion agreeing to participate in continuous remote care in Group 1 at baseline versus at 3.5 months in Group 2

    Time frame: Baseline in Group 1 versus 3.5 months in Group 2

  2. Change in fasting triglyceride/HDL ratio

    Among Group 1 versus Group 2 subjects, change from in fasting triglyceride/HDL ratio

    Time frame: Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus 10 months

  3. Change in LDL-cholesterol

    Among Group 1 versus Group 2 subjects, change from in LDL-cholesterol

    Time frame: Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus 10 months

  4. Change in fasting glucose

    Among Group 1 versus Group 2 subjects, change from in fasting glucose

    Time frame: Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus 10 months

  5. Acceptance/continuation of referral to continuous remote care

    Among Group 1 subjects, proportion agreeing to participate in continuous remote care

    Time frame: Baseline and 3.5 months

  6. Continuation of referral in Group 1 versus acceptance of referral in Group 2

    Among Group 1 versus Group 2 subjects, proportion agreeing to participate/continue in continuous remote care

    Time frame: 3.5 months

  7. Change in perceived health status

    Among Group 1 and Group 2 subjects, evaluation over time (i.e. 3 months post-intervention) in perceived health status as assessed by question 1 of the Short Form Health Survey (SF-1).

    Time frame: Baseline, 3.5 months, 7 months and 10 months

  8. Change in diabetes treatment satisfaction

    Among Group 1 and Group 2 subjects, evaluation over time at baseline, in diabetes treatment satisfaction as assessed by the Diabetes Treatment Satisfaction Questionnaire. The scale for the survey questions is 0-6. In general, a higher score indicates a higher level of satisfaction with diabetic treatment.

    Time frame: Baseline, 3.5 months, 7 months and 10 months

  9. Count of 2-way contacts among subjects

    Among Group 1 and Group 2 subjects, evaluation in active engagement as assessed by number of 2-way contacts.

    Time frame: 3.5 months and 7 months

  10. Acceptability of referral

    Among Group 1 subjects at baseline 3.5 and 7 months, and Group 2 subjects at 3.5 and 7 months. Participants will be asked 'Did you complete the referral to Virta Health?' Yes/No

    Time frame: Group 1: baseline, 3.5 months and 7 months / Group 2: 3.5 months and 7 months

  11. Acceptability of referral over time

    Among Group 1 subjects at baseline 3.5 and 7 months, and Group 2 subjects at 3.5 and 7 months. Participants will be asked if they are still continuing their treatment with Virta Health.

    Time frame: Group 1: baseline, 3.5 months and 7 months / Group 2: 3.5 months and 7 months

07

Study locations

3 sites
  • Northwest Colorado Health - Community Health Center & Prevention Services Craig
    Craig, Colorado 81625, United States
  • High Plains Community Health Center
    Lamar, Colorado 81052, United States
  • Chaffee County Public and Environmental Health
    Salida, Colorado 81201, United States
08

References and documents

Publications

  • Yaemsiri S, Alfier JM, Moy E, Rossen LM, Bastian B, Bolin J, Ferdinand AO, Callaghan T, Heron M. Healthy People 2020: Rural Areas Lag In Achieving Targets For Major Causes Of Death. Health Aff (Millwood). 2019 Dec;38(12):2027-2031. doi: 10.1377/hlthaff.2019.00915. PubMed 31794308 ↗
  • American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S7-S14. doi: 10.2337/dc21-S001. PubMed 33298412 ↗
  • Lee JY, Lee SWH. Telemedicine Cost-Effectiveness for Diabetes Management: A Systematic Review. Diabetes Technol Ther. 2018 Jul;20(7):492-500. doi: 10.1089/dia.2018.0098. Epub 2018 May 29. PubMed 29812965 ↗
  • McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, Glon RM, McCarter JP, Volek JS, Phinney SD. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. JMIR Diabetes. 2017 Mar 7;2(1):e5. doi: 10.2196/diabetes.6981. PubMed 30291062 ↗
  • Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, Campbell WW, McCarter JP, Phinney SD, Volek JS. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. Cardiovasc Diabetol. 2018 May 1;17(1):56. doi: 10.1186/s12933-018-0698-8. PubMed 29712560 ↗
  • Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, Hazbun TL, Volk BM, McCarter JP, Phinney SD, Volek JS. Author Correction: Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018 Apr;9(2):613-621. doi: 10.1007/s13300-018-0386-4. PubMed 29508274 ↗
  • Krantz MJ, Coronel SM, Whitley EM, Dale R, Yost J, Estacio RO. Effectiveness of a community health worker cardiovascular risk reduction program in public health and health care settings. Am J Public Health. 2013 Jan;103(1):e19-27. doi: 10.2105/AJPH.2012.301068. Epub 2012 Nov 15. PubMed 23153152 ↗
  • Centers for Disease Control and Prevention. Diabetes Basics: Type 2 diabetes. Page last reviewed: May 30, 2019. https://www.cdc.gov/diabetes/basics/type2.html. Accessed 06 January 2021.
  • Kazemian P, Shebl FM, McCann N, Walensky RP, Wexler DJ. Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016. JAMA Intern Med. 2019 Oct 1;179(10):1376-1385. doi: 10.1001/jamainternmed.2019.2396. PubMed 31403657 ↗
  • Stellefson M, Dipnarine K, Stopka C. The chronic care model and diabetes management in US primary care settings: a systematic review. Prev Chronic Dis. 2013;10:E26. doi: 10.5888/pcd10.120180. PubMed 23428085 ↗
  • Egbujie BA, Delobelle PA, Levitt N, Puoane T, Sanders D, van Wyk B. Role of community health workers in type 2 diabetes mellitus self-management: A scoping review. PLoS One. 2018 Jun 1;13(6):e0198424. doi: 10.1371/journal.pone.0198424. eCollection 2018. PubMed 29856846 ↗
  • Understanding Scope and Competencies: A Contemporary Look at the United States Community Health Worker Field: Progress Report of the Community Health Worker (CHW) Core Consensus (C3) Project: Building National Consensus on CHW Core Roles, Skills, and Qualities [Internet], 2016. Available from: http://files.ctctcdn.com/a907c850501/1c1289f0-88cc-49c3-a238-66def942c147.pdf. Accessed 04 November 2020.
  • Lee SWH, Chan CKY, Chua SS, Chaiyakunapruk N. Comparative effectiveness of telemedicine strategies on type 2 diabetes management: A systematic review and network meta-analysis. Sci Rep. 2017 Oct 4;7(1):12680. doi: 10.1038/s41598-017-12987-z. PubMed 28978949 ↗
  • Faruque LI, Wiebe N, Ehteshami-Afshar A, Liu Y, Dianati-Maleki N, Hemmelgarn BR, Manns BJ, Tonelli M; Alberta Kidney Disease Network. Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. CMAJ. 2017 Mar 6;189(9):E341-E364. doi: 10.1503/cmaj.150885. Epub 2016 Oct 31. PubMed 27799615 ↗
  • Marcolino MS, Maia JX, Alkmim MB, Boersma E, Ribeiro AL. Telemedicine application in the care of diabetes patients: systematic review and meta-analysis. PLoS One. 2013 Nov 8;8(11):e79246. doi: 10.1371/journal.pone.0079246. eCollection 2013. PubMed 24250826 ↗
  • American Diabetes Association. 5. Facilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S53-S72. doi: 10.2337/dc21-S005. PubMed 33298416 ↗
  • Sainsbury E, Kizirian NV, Partridge SR, Gill T, Colagiuri S, Gibson AA. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2018 May;139:239-252. doi: 10.1016/j.diabres.2018.02.026. Epub 2018 Mar 6. PubMed 29522789 ↗
  • Snorgaard O, Poulsen GM, Andersen HK, Astrup A. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2017 Feb 23;5(1):e000354. doi: 10.1136/bmjdrc-2016-000354. eCollection 2017. PubMed 28316796 ↗
  • Athinarayanan SJ, Adams RN, Hallberg SJ, McKenzie AL, Bhanpuri NH, Campbell WW, Volek JS, Phinney SD, McCarter JP. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. Front Endocrinol (Lausanne). 2019 Jun 5;10:348. doi: 10.3389/fendo.2019.00348. eCollection 2019. PubMed 31231311 ↗
  • Senn S. Crossover Trials in Clinical Research. (1993) John Wiley & Sons, New York.
  • Littell RC, et al. SASA System for Linear Models. (1991) Third edition, Cary, NC. SAS Institute, Inc.
  • United States Food and Drug Administration. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1). Guidance for Industry. OMB Control No. 0910-0843. March, 2018

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2024, 41 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 41 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2021
First posted
Mar 19, 2021
StartActual
Mar 2, 2021
Primary completionActual
Aug 30, 2024
CompletionActual
Aug 30, 2024
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04807218
Lead sponsor
Colorado Prevention Center
Collaborators
Virta Health
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Mar 2, 2021
Primary completion
Aug 30, 2024
Completion
Aug 30, 2024
Last update
Mar 11, 2025

Study contacts

Cecilia Low Wang, MD
principal investigator · CPC Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion